Table of Contents
International Journal of Molecular Imaging
Volume 2011, Article ID 372509, 11 pages
Review Article

The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II

1Department of Neuroscience, Neurology, University Hospital, Uppsala University, 751 85 Uppsala, Sweden
2Department of Radiation-Oncology (MAASTRO), GROW (School for Oncology and Developmental Biology), Maastricht University Medical Centre (MUMC), 6202 Maastricht, The Netherlands

Received 21 October 2010; Revised 15 January 2011; Accepted 25 January 2011

Academic Editor: Ronald L. Van Heertum

Copyright © 2011 Anja Smits and Brigitta G. Baumert. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The clinical management of adults with low-grade gliomas (LGGs) remains a challenge. There is no curative treatment, and management of individual patients is a matter of deciding optimal timing as well as right treatment modality. In addition to conventional imaging techniques, positron emission tomography (PET) with amino acid tracers can facilitate diagnostic and therapeutic procedures. In this paper, the clinical applications of PET with amino acid tracers 11C-methyl-L-methionine (MET) and 18F-fluoro-ethyl-L-tyrosine (FET) for patients with LGG are summarized. We also discuss the value of PET for the long-term followup of this patient group. Monitoring metabolic activity by PET in individual patients during course of disease will provide insight in the biological behavior and evolution of these tumors. As such, spatial changes in tumor activity over time, including shifts of hot-spot regions within the tumor, may reflect intratumoral heterogeneity and correlate to clinical parameters.